Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with ...

John Ryan, a U.S. Navy veteran, beat cancer through nearly a decade of experimental immunotherapy treatment. The vet shared ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...